Therapy Areas: Autoimmune
Kangpu Biopharmaceuticals doses first patient in US Phase IIa clinical trial of KPG-818
13 June 2022 -

Kangpu Biopharmaceuticals, a China-based clinical-stage company, announced on Sunday that it has dosed its first patient in the United States Phase IIa clinical trial of KPG-818, an orally bioavailable NeoMIDESTM molecular glue, intended to treat systemic lupus erythematosus (SLE).

The Phase IIa trial, a multicentre, randomised, double-blind, placebo-controlled clinical study, is intended to assess the safety and tolerability, pharmacokinetics, and preliminary efficacy of KPG-818 in patients with SLE.

The product is a novel cereblon E3 ubiquitin ligase complex (CRL4-CRBN) modulator, produced by the company for the treatment of autoimmune diseases and hematologic malignancies. During a Phase Ib clinical study in SLE recently completed in the United States, the company stated that KPG-818 showcased good tolerability, a favourable pharmacokinetic profile, and substantial potency for the degradation of Ikaros and Aiolos (IKZF1 and IKZF3).

Login
Username:

Password: